Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2315558 | 1.00 | HTR6 (0.48) | HTR6HTR2BSMN1; SMN2RAB9APOLB | |
| SCHEMBL2315550 | 1.00 | HTR6 (0.48) | HTR6HTR2BSMN1; SMN2RAB9APOLB | |
| SCHEMBL12872129 | 0.87 | HTR6 (0.54) | HTR6HTR2B | |
| SCHEMBL7997566 | 0.87 | HTR6 (0.55) | HTR6HTR2B | |
| SCHEMBL1178934 | 0.87 | HTR6 (0.55) | HTR6HTR2B | |
| SCHEMBL1178930 | 0.87 | HTR6 (0.55) | HTR6HTR2B | |
| SCHEMBL7996663 | 0.83 | HTR6 (0.56) | HTR6HTR2B | |
| SCHEMBL1179907 | 0.83 | HTR6 (0.56) | HTR6HTR2B | |
| SCHEMBL1179902 | 0.83 | HTR6 (0.56) | HTR6HTR2B | |
| SCHEMBL7988722 | 0.83 | HTR6 (0.49) | HTR6HTR2BALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422244-B2 | Synthesis of substituted pyrazoline carboxamidine derivatives | ABBVIE BAHAMAS LTD. (BS) | 2016-08-23 | — | — | US | disclosed |
| US-9422244-B2 | Synthesis of substituted pyrazoline carboxamidine derivatives | ABBVIE BAHAMAS LTD. (BS) | 2016-08-23 | — | — | US | disclosed |
| US-20140303372-A1 | SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BHAMAS LTD. (BS) | 2014-10-09 | — | — | US | disclosed |
| US-20140303372-A1 | SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BHAMAS LTD. (BS) | 2014-10-09 | — | — | US | disclosed |
| EP-2528900-B1 | SYNTHESIS OF SUBSTITUTED PYRAZOLINE CARBOXAMIDINE DERIVATIVES | ABBVIE BAHAMAS LTD (BS) | 2014-06-11 | — | — | EP | disclosed |
| US-8722887-B2 | Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-HT6 antagonists | Abbvie Bahamas, Ltd. (BS) | 2014-05-13 | — | — | US | disclosed |
| US-8722887-B2 | Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-HT6 antagonists | Abbvie Bahamas, Ltd. (BS) | 2014-05-13 | — | — | US | disclosed |
| US-20130060041-A1 | SYNTHESIS OF SUBSTITUTED PYRAZOLINE CARBOXAMIDINE DERIVATIVES | ABBOTT HOSPITALS LIMITED (BS) | 2013-03-07 | — | — | US | disclosed |
| US-20130060041-A1 | SYNTHESIS OF SUBSTITUTED PYRAZOLINE CARBOXAMIDINE DERIVATIVES | ABBOTT HOSPITALS LIMITED (BS) | 2013-03-07 | — | — | US | disclosed |
| WO-2011092226-A1 | SYNTHESIS OF SUBSTITUTED PYRAZOLINE CARBOXAMIDINE DERIVATIVES | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2011-08-04 | — | — | WO | disclosed |
| US-20100145042-A1 | SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | SOLVAY PHARMACEUTICALS B.V. | 2010-06-10 | — | — | US | disclosed |
| US-20100145042-A1 | SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | SOLVAY PHARMACEUTICALS B.V. | 2010-06-10 | — | — | US | disclosed |
| US-7728018-B2 | for treating disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, sleep, eating disorders | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-06-01 | — | — | US | disclosed |
| US-7728018-B2 | for treating disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, sleep, eating disorders | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-06-01 | — | — | US | disclosed |
| US-20080311179-A1 | for treating disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, sleep, eating disorders | ABBOTT HOSPITALS LIMITED (BS) | 2008-12-18 | — | — | US | disclosed |
| US-20080311179-A1 | for treating disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, sleep, eating disorders | ABBOTT HOSPITALS LIMITED (BS) | 2008-12-18 | — | — | US | disclosed |
| WO-2008034863-A2 | SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311179-A1 | for treating disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, sleep, eating disorders | HTR6, HCRTR2, HTR2C | HTR6 1/4885HTR2B 6/4885SMN1; SMN2 706/4885 |
| US-20100145042-A1 | SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | HTR6 1/4885HTR2B 6/4885SMN1; SMN2 471/4885 |
| US-20140303372-A1 | SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | HTR6 1/4885HTR2B 6/4885SMN1; SMN2 471/4885 |
| US-20130060041-A1 | SYNTHESIS OF SUBSTITUTED PYRAZOLINE CARBOXAMIDINE DERIVATIVES | HTR6, HTR5A, HTR4 | HTR6 1/4885HTR2B 16/4885SMN1; SMN2 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.